-
公开(公告)号：EP2427201B1
公开(公告)日：2015-01-28
申请号：EP10747684.8
申请日：2010-05-03
CPC分类号： A61K39/165 , A61K35/13 , A61K38/2013 , A61K39/0015 , A61K39/015 , A61K39/12 , A61K2039/5256 , A61K2039/53 , A61K2039/54 , A61K2039/55566 , A61K2039/55588 , A61K2039/575 , A61K2039/70 , C12N7/00 , C12N2760/18421 , C12N2760/18434 , C12N2760/18442 , C12N2760/18443 , Y02A50/412
摘要： The present invention relates to a combined measles-malaria vaccine containing different attenuated recombinant measles-malaria vectors comprising a heterologous nucleic acid encoding several Plasmodium falciparum antigens. Preferably, it relates to viral vectors that comprise nucleic acids encoding the circumsporozoite (CS) protein of P . falciparum, the merozoite surface protein 1 (MSP-I) of P. falciparum, and its derivatives (p-42; p-83-30-38) in its glycosylated and secreted forms, and apical membrane antigen 1 (AMA1) of P . falciparum, and its anchored or secreted form. The viral vector stems from an attenuated measles virus, based on a strain that is used as a vaccine and is efficient in delivering the gene of interest and that binds to and infects the relevant immune cells efficiently. In a preferred embodiment, the CS, the MSP1 and the AMA1 proteins are generated from the virus such that they will give rise to a potent immune response in mammals, preferably humans; the expression of the proteins is elevated due to human codon optimisation. Furthermore, the invention relates to the use of the recombinant vaccine in the prophylactic treatment of malaria.
-
公开(公告)号：EP2427201A2
公开(公告)日：2012-03-14
申请号：EP10747684.8
申请日：2010-05-03
CPC分类号： A61K39/165 , A61K35/13 , A61K38/2013 , A61K39/0015 , A61K39/015 , A61K39/12 , A61K2039/5256 , A61K2039/53 , A61K2039/54 , A61K2039/55566 , A61K2039/55588 , A61K2039/575 , A61K2039/70 , C12N7/00 , C12N2760/18421 , C12N2760/18434 , C12N2760/18442 , C12N2760/18443 , Y02A50/412
摘要： The present invention relates to a combined measles-malaria vaccine containing different attenuated recombinant measles-malaria vectors comprising a heterologous nucleic acid encoding several Plasmodium falciparum antigens. Preferably, it relates to viral vectors that comprise nucleic acids encoding the circumsporozoite (CS) protein of P . falciparum, the merozoite surface protein 1 (MSP-I) of P. falciparum, and its derivatives (p-42; p-83-30-38) in its glycosylated and secreted forms, and apical membrane antigen 1 (AMA1) of P . falciparum, and its anchored or secreted form. The viral vector stems from an attenuated measles virus, based on a strain that is used as a vaccine and is efficient in delivering the gene of interest and that binds to and infects the relevant immune cells efficiently. In a preferred embodiment, the CS, the MSP1 and the AMA1 proteins are generated from the virus such that they will give rise to a potent immune response in mammals, preferably humans; the expression of the proteins is elevated due to human codon optimisation. Furthermore, the invention relates to the use of the recombinant vaccine in the prophylactic treatment of malaria.
-
公开(公告)号：EP2818175B1
公开(公告)日：2018-11-21
申请号：EP14168608.9
申请日：2010-05-03
IPC分类号： A61K35/76 , A61P33/06 , A61K38/15 , A61K39/165 , A61K39/295 , C12N7/01 , C12N15/09 , C12N7/02 , C12N7/04 , C12N7/08
CPC分类号： A61K39/165 , A61K35/13 , A61K38/2013 , A61K39/0015 , A61K39/015 , A61K39/12 , A61K2039/5256 , A61K2039/53 , A61K2039/54 , A61K2039/55566 , A61K2039/55588 , A61K2039/575 , A61K2039/70 , C12N7/00 , C12N2760/18421 , C12N2760/18434 , C12N2760/18442 , C12N2760/18443 , Y02A50/412
摘要： The present invention relates to a combined measles-malaria vaccine containing different attenuated recombinant measles-malaria vectors comprising a heterologous nucleic acid encoding several Plasmodium falciparum antigens. Preferably, it relates to viral vectors that comprise nucleic acids encoding the circumsporozoite (CS) protein of P . falciparum, the merozoite surface protein 1 (MSP-I) of P. falciparum, and its derivatives (p-42; p-83-30-38) in its glycosylated and secreted forms, and apical membrane antigen 1 (AMA1) of P . falciparum, and its anchored or secreted form. The viral vector stems from an attenuated measles virus, based on a strain that is used as a vaccine and is efficient in delivering the gene of interest and that binds to and infects the relevant immune cells efficiently. In a preferred embodiment, the CS, the MSP1 and the AMA1 proteins are generated from the virus such that they will give rise to a potent immune response in mammals, preferably humans; the expression of the proteins is elevated due to human codon optimisation. Furthermore, the invention relates to the use of the recombinant vaccine in the prophylactic treatment of malaria.
-
公开(公告)号：EP2818175A1
公开(公告)日：2014-12-31
申请号：EP14168608.9
申请日：2010-05-03
IPC分类号： A61K35/76 , A61P33/06 , A61K38/15 , A61K39/165 , A61K39/295 , C12N7/01 , C12N15/09 , C12N7/02 , C12N7/04 , C12N7/08
CPC分类号： A61K39/165 , A61K35/13 , A61K38/2013 , A61K39/0015 , A61K39/015 , A61K39/12 , A61K2039/5256 , A61K2039/53 , A61K2039/54 , A61K2039/55566 , A61K2039/55588 , A61K2039/575 , A61K2039/70 , C12N7/00 , C12N2760/18421 , C12N2760/18434 , C12N2760/18442 , C12N2760/18443 , Y02A50/412
摘要： The present invention relates to a combined measles-malaria vaccine containing different attenuated recombinant measles-malaria vectors comprising a heterologous nucleic acid encoding several Plasmodium falciparum antigens. Preferably, it relates to viral vectors that comprise nucleic acids encoding the circumsporozoite (CS) protein of P . falciparum, the merozoite surface protein 1 (MSP-I) of P. falciparum, and its derivatives (p-42; p-83-30-38) in its glycosylated and secreted forms, and apical membrane antigen 1 (AMA1) of P . falciparum, and its anchored or secreted form. The viral vector stems from an attenuated measles virus, based on a strain that is used as a vaccine and is efficient in delivering the gene of interest and that binds to and infects the relevant immune cells efficiently. In a preferred embodiment, the CS, the MSP1 and the AMA1 proteins are generated from the virus such that they will give rise to a potent immune response in mammals, preferably humans; the expression of the proteins is elevated due to human codon optimisation. Furthermore, the invention relates to the use of the recombinant vaccine in the prophylactic treatment of malaria.
摘要翻译： 本发明涉及含有不同的减毒重组麻疹 - 疟疾载体的麻疹 - 疟疾联合麻疹疫苗，其包含编码几种恶性疟原虫抗原的异源核酸。 优选地，其涉及包含编码P的环子孢子（CS）蛋白的核酸的病毒载体。 恶性疟原虫，其恶性疟原虫的裂殖子表面蛋白1（MSP-1）及其衍生物（p-42; p-83-30-38）以其糖基化和分泌形式，以及P的顶端膜抗原1（AMA1） 。 恶性疟原虫及其锚定或分泌形式。 病毒载体源自减毒的麻疹病毒，其基于用作疫苗的菌株，并且有效地递送目标基因并有效地结合并感染相关的免疫细胞。 在优选的实施方案中，CS，MSP1和AMA1蛋白是从病毒产生的，使得它们将在哺乳动物，优选人中产生有效的免疫应答; 由于人类密码子优化，蛋白质的表达升高。 此外，本发明涉及重组疫苗在预防性治疗疟疾中的用途。
-
-
-
搜索结果
4 条记录 (耗时 0.012 秒)
